The fair value of BioStem Technologies, a manufacturer of perinatal tissue-based treatments, should be nearly 80% higher than the current share price, according to Zacks Small-Cap Research (Zacks SCR). BioStem has seen rapid growth recently, and its second-quarter 2024 earnings beat expectations, Zacks SCR points out. BioStem stock rose 8.4%…